The role of neoadjuvant and adjuvant chemotherapy in the treatment of patients with lung cancer (review)
Summary. Today, lung cancer (LC) is the leader in the morbidity and mortality rate of malignant neoplasms in the world. Every year, more than 1.6 million of new cases of LC are diagnosed in the world, and mortality from LC is more than 1.2 million. Suggest that in 2035, mortality from LC will be 3 million people per year. Leaders in morbidity are Central and Eastern Europe (53.5 cases per 100,000 population). In this article modern approaches to neoadjuvant polychemotherapy (NAPCT) and adjuvant polychemotherapy (APCT) in the treatment of patients with non-small cell LC were analyzed according on the grounds of specialized literature. NAPCT and APCT are important stages in the treatment of patients with LC, because it allows can improve overall and disease-free survival of patients. When NAСT is performed, a radical resection of R0 can be achieved in 40.0% for pemetrexed/cisplatin, 29.0% for carboplatin/paclitaxel and 18.0% for cisplatin/vinblastin. The toxicity profile is an integral part of the choice scheme of polychemotherapy. The better tolerance of the scheme increases the number of chemotherapy cycles, which improves survival and quality of life. The regimen of the cisplatin/vindesin tolerability was from 45.0 to 69.0%, with carboplatin/paclitaxel was 57% and pemetrexed/cisplatin was 81.0%.
No Comments » Add your